Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Show more

Location: 80 Guest Street, Boston, MA, 02135, United States | Website: https://www.aurabiosciences.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

389.4M

52 Wk Range

$4.34 - $12.38

Previous Close

$6.28

Open

$6.27

Volume

133,863

Day Range

$6.06 - $6.36

Enterprise Value

206.1M

Cash

128M

Avg Qtr Burn

-19.68M

Insider Ownership

1.98%

Institutional Own.

76.23%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.